Diagnostics - Our Strategic Focus

With our many years' experience in in-vitro diagnostic test kits, we are focusing on Bone & Ca Metabolism and FABP (Fatty-Acid Binding Protein). We also aim at developing novel biomarkers to address the unmet medical need in diagnostic field.

Bone & Ca Metabolism


Bone & Ca - Trap-5b®

DS Pharma Biomedical has been a leading company in-vitro diagnostics area over the decades. Our trusted relationship with key opinion leaders in this field has been creating an invaluable platform for our clinical development program of our unique diagnostic test kits.
Our Osteolinks® TRAP-5b® test kit is such an example, and is raising keen interest among medical professionals as an excellent IVD test kit, which enables them to specifically quantify blood TRACP-5b (Tartrate Resistant Acid Phosphatase-5b), a highly sensitive bone absorption marker. Learn More >>

We will continue our focus on the development of IVD test kits for Bone and Ca metabolism.

Point of Care Testing (POCT)


DS Pharma Biomedical has been a pioneer in introducing rapid test kits of Influenza virus and Group-A beta-hemolytic Streptococcus, and is proud of its contribution to the solid penetration of POCT kits in Japan.
We strive to continue our effort in developing more rapid, accurate and user-friendly test kits for patients and medical professionals.

H-FABP & Other New Biomarker

Rapichek® H-FABP

Liblia® H-FABP

Rapicheck® H-FABP & Liblia® H-FABP

H-FABP (Heart-type Fatty Acid-Binding Protein) is a cytoplasmic protein located in myocardial cells and easily leaks into blood stream by cell injury. We developed immunological assay kits for H-FABP which permit early diagnosis of myocardial infarction.

We currently offer Rapicheck® H-FABP (immunochromatography, qualitative), Learn More >>
and Liblia® H-FABP (latex agglutination turbidimetry, quantitative). Learn More >>.

Using a series of our proprietary antibodies against FABP family proteins, we established latex reagent for I-FABP (Intestinal Fatty Acid Binding Protein) and have been developing I-FABP as a biomarker for small intestine diseases.

Our Expertise in establishing antibodies and immunoassay system has been our driving force for developing new biomarkers.